Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement: Meta-Analysis of Kaplan-Meier-Derived Individual Patient Data

• Published in: JACC. Cardiovascular imaging Vol. 16; no. 3; pp. 298 - 310
• Main Authors: Sá, Michel Pompeu, Jacquemyn, Xander, Van den Eynde, Jef, Tasoudis, Panagiotis, Dokollari, Aleksander, Torregrossa, Gianluca, Sicouri, Serge, Clavel, Marie-Annick, Pibarot, Philippe, Ramlawi, Basel
• Format: Journal Article
• Language: English
• Published: United States 01.03.2023
• Subjects: Aortic Valve - diagnostic imaging; Aortic Valve - surgery; Aortic Valve Stenosis - diagnostic imaging; Aortic Valve Stenosis - surgery; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Predictive Value of Tests; Prosthesis Design; Risk Factors; Transcatheter Aortic Valve Replacement - adverse effects; Treatment Outcome; meta-analysis; transcatheter aortic valve replacement; heart valve diseases; heart valve prosthesis implantation; cardiac surgical procedures; cardiovascular surgical procedures
• ISSN: 1876-7591
• DOI: 10.1016/j.jcmg.2022.07.013

It remains controversial whether prosthesis-patient mismatch (PPM) (in general considered moderate if indexed effective orifice area is 0.65-0.85 cm /m and severe when <0.65 cm /m ) affects the outcomes after transcatheter aortic valve replacement (TAVR). The purpose of this study is to evaluate the time-varying effects and association of PPM with the risk of overall mortality. Study-level meta-analysis of reconstructed time-to-event data from Kaplan-Meier curves of studies published by December 30, 2021. In total, 23 studies met our eligibility criteria and included a total of 81,969 patients included in the Kaplan-Meier curves (19,612 with PPM and 62,357 without PPM). Patients with moderate/severe PPM had a significantly higher risk of mortality compared with those without PPM (HR: 1.09 [95% CI: 1.04-1.14]; P < 0.001). In the first 30 months after the procedure, mortality rates were significantly higher in the moderate/severe PPM group (HR: 1.1 [95% CI: 1.05-1.16]; P < 0.001). In contrast, the landmark analysis beyond 30 months yielded a reversal of the HR (0.83 [95% CI: 0.68-1.01]; P = 0.064), but without statistical significance. In the sensitivity analysis, although the authors observed that severe PPM showed higher risk of mortality in comparison with no PPM (HR: 1.25 [95% CI: 1.16-1.36]; P < 0.001), they did not observe a statistically significant difference for mortality between moderate PPM and no PPM (HR: 1.03 [95% CI: 0.96-1.10]; P = 0.398). Severe PPM, but not moderate PPM, was associated with higher risk of mortality following TAVR. These results provide support to implementation of preventive strategies to avoid severe PPM following TAVR.